Phase 2 trial of recombinant tumor necrosis factor-α in combination with dactinomycin in children with recurrent wilms tumor

Journal of Immunotherapy

Volumn 31, Issue 7, 2008, Pages 679-683

  Meany, Holly J ^a,b   Seibel, Nita L ^a,b   Sun, Junfeng ^c,d   Finklestein, Jerry Z ^e   Sato, Judith ^f   Kelleher, John ^g   Sondel, Paul ^h   Reaman, Gregory ^a,b,d  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e MILLER CHILDREN S HOSPITAL   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g AMGEN INC   (United States)

^h UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Pediatric; Phase 2; Tumor necrosis factor; Wilms tumor

Indexed keywords

CARBOPLATIN; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE; ANTINEOPLASTIC AGENT; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CAPILLARY LEAK SYNDROME; CEREBELLUM DISEASE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEMATURIA; HUMAN; HYPOTENSION; INFANT; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MOOD; MOTOR DYSFUNCTION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROBLASTOMA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; STOMATITIS; SYSTOLIC BLOOD PRESSURE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; GENETICS; KIDNEY TUMOR; LEUKOCYTE DISORDER; PATHOLOGY; PRESCHOOL CHILD; TUMOR RECURRENCE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DACTINOMYCIN; FEMALE; HUMANS; INFANT; KIDNEY NEOPLASMS; LEUKOCYTE DISORDERS; MALE; NEOPLASM RECURRENCE, LOCAL; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; WILMS TUMOR;

EID: 63849306606     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181826d72     Document Type: Article

References (19)

1. Jones AL, Selby P. Clinical applications of tumour necrosis factor. Prog Growth Factor Res. 1989;1:107-122.
2. Darzynkiewicz Z, Williamson B, Carswell EA, et al. Cell cycle-specific effects of tumor necrosis factor. Cancer Res. 1984;44: 83-90.
3. Nakano K, Abe S, Sohmura Y. Recombinant human tumor necrosis factor-I. Cytotoxic activity in vitro. Int J Immunopharmacol. 1986;8: 347-355.
4. Watanabe N, Niitsu Y, Yamauchi N, et al. Synergistic cytotoxicity of recombinant human TNF and various anti-cancer drugs. Immunopharmacol Immunotoxicol. 1988;10:117-127.
5. Alexander RB, Nelson WG, Coffey DS. Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res. 1987;47: 2403-2406.
6. Gatanaga T, Takahashi K, Yamazaki M, et al. Combination antitumor therapy with rabbit tumor necrosis factor and chemoand immuno-therapeutic agents against murine tumors. Jpn J Cancer Res. 1985;76:631-636.
7. Darzynkiewicz Z, Carter SP, Old LJ. Effect of recombinant tumor necrosis factor on HL-60 cells: cell-cycle specificity and synergism with actinomycin D. J Cell Physiol. 1987;130:328-335.
8. Lejeune FJ, Lienard D, Matter M, et al. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 2006;6:6.
9. Feinberg B, Kurzrock R, Talpaz M, et al. A phase I trial of intravenously-administered recombinant tumor necrosis factoralpha in cancer patients. J Clin Oncol. 1988;6:1328-1334.
10. Blick M, Sherwin SA, Rosenblum M, et al. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res. 1987;47:2986-2989.
11. Chapman PB, Lester TJ, Casper ES, et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol. 1987;5:1942-1951.
12. Furman WL, Strother D, McClain K, et al. Phase I clinical trial of recombinant human tumor necrosis factor in children with refractory solid tumors: a Pediatric Oncology Group study. J Clin Oncol. 1993;11:2205-2210.
13. Seibel NL, Dinndorf PA, Bauer M, et al. Phase I study of tumor necrosis factor-alpha and actinomycin D in pediatric patients with cancer: a Children's Cancer Group study. J Immunother Emphasis Tumor Immunol. 1994;16:125-131.
14. Farber S. Chemotherapy in the treatment of leukemia and Wilms' tumor. JAMA. 1966;198:826-836.
15. Metzger ML, Dome JS. Current therapy for Wilms' tumor. Oncologist. 2005;10:815-826.
16. Green DM, Cotton CA, Malogolowkin M, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D. a report from the National Wilms Tumor Study Group. Pediatr Blood Cancer. 2007;48:493-499.
17. Green DM, Breslow NE, Beckwith JB, et al. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol. 1998;16: 237-245.
18. Veal GJ, Cole M, Errington J, et al. Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Group Study. Clin Cancer Res. 2005;11: 5893-5899.
19. Shannon A, Smith J, Nagel K, et al. Selective thrombocytopenia in children with Wilms tumor: an immune-mediated effect of dactinomycin? Med Pediatr Oncol. 2003;41:483-485.